108 related articles for article (PubMed ID: 11506395)
1. Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study.
Kingsbury AE; Cooper M; Schapira AH; Foster OJ
Ann Neurol; 2001 Aug; 50(2):142-9. PubMed ID: 11506395
[TBL] [Abstract][Full Text] [Related]
2. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Kingsbury AE; Marsden CD; Foster OJ
Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
Yamada M; Yamada M; Richelson E
Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
[TBL] [Abstract][Full Text] [Related]
4. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain.
Yamada M; Groshan K; Phung CT; Yamada M; Hisamitsu T; Richelson E
Brain Res Mol Brain Res; 1997 Feb; 44(1):12-20. PubMed ID: 9030693
[TBL] [Abstract][Full Text] [Related]
5. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
Counihan TJ; Penney JB
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
7. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.
Kastner A; Hirsch EC; Agid Y; Javoy-Agid F
Brain Res; 1993 Mar; 606(2):341-5. PubMed ID: 8098254
[TBL] [Abstract][Full Text] [Related]
9. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
10. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
11. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?
Kingsbury AE; Mardsen CD; Foster OJ
Mov Disord; 1998 Nov; 13(6):877-84. PubMed ID: 9827610
[TBL] [Abstract][Full Text] [Related]
12. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
13. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
14. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
Hartmann A; Michel PP; Troadec JD; Mouatt-Prigent A; Faucheux BA; Ruberg M; Agid Y; Hirsch EC
J Neurochem; 2001 Mar; 76(6):1785-93. PubMed ID: 11259496
[TBL] [Abstract][Full Text] [Related]
15. Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon.
Zhang P; Damier P; Hirsch EC; Agid Y; Ceballos-Picot I; Sinet PM; Nicole A; Laurent M; Javoy-Agid F
Neuroscience; 1993 Jul; 55(1):167-75. PubMed ID: 8350985
[TBL] [Abstract][Full Text] [Related]
16. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons.
Counihan TJ; Landwehrmeyer GB; Standaert DG; Kosinski CM; Scherzer CR; Daggett LP; Veliçelebi G; Young AB; Penney JB
J Comp Neurol; 1998 Jan; 390(1):91-101. PubMed ID: 9456178
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
19. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
20. Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders.
Vyas S; Javoy-Agid F; Herrero MT; Strada O; Boissiere F; Hibner U; Agid Y
J Neurochem; 1997 Jul; 69(1):223-31. PubMed ID: 9202314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
